| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.21037/TLCR.2017.04.03 |
| P8608 | Fatcat ID | release_vi46jcwiznfhtlto3sig76lifu |
| P932 | PMC publication ID | 5420533 |
| P698 | PubMed publication ID | 28529895 |
| P50 | author | Daniel Gomez | Q100742655 |
| P2093 | author name string | Tracey Evans | |
| Christine Ciunci | |||
| Lauren Hertan | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Systemic Immunotherapy for the Treatment of Brain Metastases | Q26750891 | ||
| Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function | Q48220006 | ||
| Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology | Q48344519 | ||
| Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies | Q48462650 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. | Q50777923 | ||
| Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. | Q51532051 | ||
| Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. | Q53391760 | ||
| Palliative retreatment of locally-recurrent lung cancer after radical radiotherapy | Q69006030 | ||
| The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation | Q72646673 | ||
| Whole body irradiation; radiobiology or medicine? | Q73123026 | ||
| Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer | Q73336669 | ||
| Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy | Q73496463 | ||
| Reirradiation for locally recurrent lung cancer previously treated with radiation therapy | Q77712000 | ||
| Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial | Q79313404 | ||
| Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy | Q82363173 | ||
| Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence | Q83406598 | ||
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | Q27853359 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated | Q28245528 | ||
| Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases | Q33620317 | ||
| Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients | Q33914974 | ||
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial | Q33926135 | ||
| Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial | Q34066501 | ||
| Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes | Q34438618 | ||
| Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses | Q35143867 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| Treatment of recurrent disease in lung cancer | Q35543234 | ||
| Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases | Q36082506 | ||
| Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer | Q36179383 | ||
| Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research | Q36663274 | ||
| Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. | Q36780663 | ||
| Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). | Q36835347 | ||
| Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer | Q36935116 | ||
| Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. | Q37148372 | ||
| Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer | Q37420376 | ||
| Ipilimumab and radiation therapy for melanoma brain metastases | Q37481186 | ||
| Systemic effects of local radiotherapy | Q37539309 | ||
| Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas | Q37658308 | ||
| Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival | Q38019011 | ||
| High-dose, conventionally fractionated thoracic reirradiation for lung tumors | Q38179125 | ||
| Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model | Q38821358 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. | Q39118471 | ||
| Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy | Q39192894 | ||
| Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells | Q39370246 | ||
| Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. | Q40483350 | ||
| Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. | Q40534742 | ||
| Radiation and immunotherapy: a synergistic combination. | Q42724344 | ||
| Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. | Q45409658 | ||
| Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy | Q46817579 | ||
| P433 | issue | 2 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 119-130 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Translational lung cancer research | Q26842616 |
| P1476 | title | Special topics in immunotherapy and radiation therapy: reirradiation and palliation | |
| P478 | volume | 6 |
| Q55312880 | Re-irradiation in lung disease by SBRT: a retrospective, single institutional study. | cites work | P2860 |
Search more.